Evidence map›Paper›PMID 42157930›Full record

ArticleInternational journal of biological sciences2026

CRL4

Yaru Sheng, Ting Ni, Xiaoyi Ding, Jiaying Huang, Xueya Zhao, Xinyao Li, Qingting Li, Jing Wang, Xiaoming Yang, Lin Zhang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yaru ShengDepartment of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Ting NiDepartment of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xiaoyi DingDepartment of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Jiaying HuangDepartment of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xueya ZhaoDepartment of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xinyao LiDepartment of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Qingting LiDepartment of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Jing WangDepartment of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xiaoming YangDepartment of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Lin ZhangDepartment of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xuan ZhengDepartment of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Dan CaoDepartment of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Rongjia SuDepartment of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xiaojing LuDepartment of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Jin HouNational Key Laboratory of Immunity and Inflammation, Institute of Immunology, Naval Medical University, Shanghai, China.
Yudong WangDepartment of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medroxyprogesterone acetate (MPA) is a major fertility-preserving therapeutic option for patients with endometrial cancer (EC); however, MPA resistance markedly restricts the efficacy of conservative treatments. Downregulation of the progesterone receptor (PR) expression is a key determinant of MPA resistance; however, the underlying molecular mechanisms have not been elucidated comprehensively. In this study, we identified AMBRA1, a substrate-specific adaptor of CUL4-RING E3 ubiquitin ligase (CRL4), as a critical regulator of PR stability and the MPA response. AMBRA1 expression was significantly increased in MPA-resistant EC tissues, and its overexpression induced an MPA-resistant phenotype. Mechanistically, AMBRA1 promotes ubiquitin-mediated degradation of PR by targeting lysine 388 in a CRL4

Indexed as

Adaptor Proteins, Signal TransducingEndometrial NeoplasmsProgestinsReceptors, ProgesteroneAnimalsCell Line, TumorDrug Resistance, NeoplasmFemaleHumansMedroxyprogesterone AcetateUbiquitin-Protein LigasesAdaptor Proteins, Signal TransducingMedroxyprogesterone AcetateProgestinsReceptors, ProgesteroneUbiquitin-Protein Ligasesendometrial cancermedroxyprogesterone acetate resistanceprogesterone receptorubiquitination modification

Identifiers

PMID42157930
PMCPMC13182556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.